This site is intended only for healthcare professionals resident in the Republic of Ireland
In a retrospective analysis of data from the INO-VATE ALL study; of the patients who received at least one dose of study drug (BESPONSA n=164 vs SC n=143), BESPONSA reduced hospitalisation burdens when compared with standard chemotherapy.1
Hospitalisation for both groups was mainly for treatment of underlying disease and toxicity associated with R/R ALL treatment including haematologic toxicity and infection.1
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023